Why the study?
The impact of continued low-dose ASA on postoperative hemorrhage and the frequency of thromboembolic events after discontinuing ASA in patients undergoing pituitary adenoma surgery remain poorly understood.
Does perioperative low-dose ASA increase the risk of postoperative hemorrhage or thromboembolism in patients undergoing pituitary adenoma surgery?
Population
108 patients who underwent surgery for primary pituitary tumors
Comparison
Patients receiving low-dose ASA medication vs those who did not
Design
Retrospective study
Authors
Loading...
Supports cautious perioperative ASA decisions in pituitary surgery; leaves open need for prospective trials before practice change.
Does perioperative low-dose ASA increase the risk of postoperative hemorrhage or thromboembolism in patients undergoing pituitary adenoma surgery?
Perioperative continuation of low-dose ASA appears safe and is not associated with an increased rate of hemorrhagic complications following pituitary adenoma surgery.
Tonchev et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: